Therapeutic nuclease compositions and methods
AssigneeUniversity of Washington
InventorsJeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
Life of this patent
Estimating the term…
Abstract
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
Claims22
A method for treating lupus nephritis in a subject in need thereof, comprising administering to the subject a composition comprising:
- a polypeptide comprising human RNase 1 operatively coupled with or without a linker to the N-terminus of an Fc domain, and DNase operatively coupled with or without a linker to the C-terminus of the Fc domain, wherein the Fc domain is a human immunoglobulin Fc domain or a mutant human immunoglobulin Fc domain, and wherein the human immunoglobulin Fc domain or mutant human immunoglobulin Fc domain comprises at least one hinge region;
- and
- a pharmaceutically acceptable carrier,
- such that treatment occurs.
A method for treating lupus nephritis in a subject in need thereof, comprising administering to the subject a composition comprising:
- (a) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 151, SEQ ID NO:
- 152, or SEQ ID NO:
- 153, with or without a leader sequence;
- or
- (b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 151, SEQ ID NO:
- 152, or SEQ ID NO:
- 153, with or without a leader sequence and comprising one or more Fc mutations selected from P238S, P331S, K322S, and N297S, numbering according to EU index;
- and
- a pharmaceutical carrier,
- such that treatment occurs.
A method for treating lupus nephritis in a subject in need thereof, comprising administering to the subject a composition comprising:
- a polypeptide comprising human RNase 1 operatively linked with or without a linker to the N-terminus of a mutant human IgG1 Fc domain, and DNase operatively linked with or without a linker to the C-terminus of the mutant Fc domain, wherein the human RNase 1 comprises the amino acid sequence set forth in SEQ ID NO:
- 149, with or without a leader sequence, and wherein the DNase comprises the amino acid sequence set forth in SEQ ID NO:
- 139, and wherein the mutant human IgG1 Fc domain comprises at least one hinge region;
- and
- a pharmaceutically acceptable carrier,
- such that treatment occurs.
Dependencies are inferred from the claim text.